Inspections, Compliance, Enforcement, and Criminal Investigations
Lancome - Close Out Letter 11/19/12
| Public Health Service Food and Drug Administration |
| 5100 Paint Branch Parkway College Park, MD 20740 |
NOV 19 2012
Paul M. Hyman
Law Offices of Hyman, Phelps & McNamara, P.C.
700 Thirteenth Street, N.W.
Suite 1200
Washington, DC 20005
Re: 273596
Dear Mr. Hyman:
The Food and Drug Administration has completed an evaluation of your corrective actions in response to our Warning Letter dated September 7, 2012. Based on our review, it appears that you have addressed the violations contained in this Warning Letter. Future FDA assessments and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act (the Act) and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future
regulatory action should violations be observed during a subsequent review of your web sites or through other means.
Sincerely,
/S/
Kathleen M. Lewis, J.D.
Team Leader
Labeling and Dietary Supplement
Compliance Team
Center for Food Safety
and Applied Nutrition
Cc:
Serge Jureidini
President
Lancome USA
575 Fifth Avenue
New York, NY 10017





Department of Health and Human Services

